You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC

Early-Stage Resectable Non-Small Cell Lung Cancer: Sharing Patient Perspectives

  • Authors: Solange Peters, MD, PhD; ​Anne-Marie Baird, PhD; ​​​Lesley Fallowfield, DBE, BSc, DPhil, FMedSci; ​​​Eric Lim, MBChB, MD, MSc, FRCS(C-Th)
  • CME / ABIM MOC Released: 5/4/2023
  • THIS ACTIVITY HAS EXPIRED FOR CREDIT
  • Valid for credit through: 5/4/2024, 11:59 PM EST
Start Activity


Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US and non-UK surgeons, oncologists, and pulmonologists.

The goal of this activity is for learners to be better able to manage early-stage resectable non-small cell lung cancer (NSCLC) by improving their understanding of key aspects of management and communication with patients throughout the disease journey.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Management strategies for patients with early-stage resectable NSCLC
  • Demonstrate greater confidence in their ability to
    • Communicate effectively with patients regarding the management of early-stage resectable NSCLC


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Disclosures for additional planners can be found here.


Moderator

  • Solange Peters, MD, PhD

    Professor of Oncology
    Medical Oncology Chair
    Lausanne University Hospital
    Lausanne, Switzerland

    Disclosures

    Solange Peters, MD, PhD, has the following relevant financial relationships: 
    Consultant or advisor for: AbbVie, Inc.; Amgen, Inc.; Arcus; AstraZeneca; Bayer; BeiGene (Beijing) Co., Ltd; Biocartis; BioInvent; Blueprint Medicines; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb Company; Clovis Oncology; Daiichi Sankyo, Inc.; Debiopharm; Eli Lilly and Company; F-Star; Fishawack; Foundation Medicine, Inc.; Genzyme Corporation; Gilead Sciences, Inc.; GlaxoSmithKline; Illumina; IQVIA; Incyte Corporation; iTeos; Janssen Biotech, Inc.; Merck Sharp & Dohme; Merck Serono; Merrimack Pharmaceuticals, Inc.; Novartis; Novocure; Nykode Therapeutics, formerly Vaccibody; PharmaMar; Promontory Therapeutics, formerly Phosplatin Therapeutics; Pfizer, Inc.; Regeneron Pharmaceuticals, Inc.; RMEI; Roche/Genentech; Sanofi; Seagen Inc.; Takeda; Vaccibody
    Speaker or member of speakers bureau for: AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb Company; Eli Lilly and Company; Foundation Medicine; Illumina; Merck Sharp & Dohme; Mirati; Novartis; Pfizer, Inc.; Roche/Genentech; Sanofi; Takeda
    Research funding from: Amgen, Inc.; AstraZeneca; BeiGene (Beijing) Co., Ltd; Bristol Myers Squibb Company; GlaxoSmithKline; Merck Sharp & Dohme; Roche/Genentech

Faculty

  • Anne Marie Baird, PhD

    President
    Lung Cancer Europe (LuCE)
    Senior Research Fellow 
    Trinity College
    Dublin, Ireland

    Disclosures

    Anne-Marie Baird, PhD, has the following relevant financial relationships: 
    Other: President of Lung Cancer Europe (LuCE). LuCE has received support from the following companies: Amgen, Inc.; AstraZeneca; Bayer; Blueprint Medicines; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb Company; Daiichi Sankyo, Inc.; Eli Lilly and Company; Janssen Biotech, Inc.; Merck; Merck Sharp & Dohme; Novartis; Novocure; Pfizer, Inc.; Regeneron Pharmaceuticals, Inc.; Roche; Sanofi; Takeda; Thermo Fisher Scientific Inc.

  • Lesley Fallowfield, DBE, BSc, DPhil, FMedSci

    Sussex Health Outcomes Research and Education in Cancer (SHORE-C)
    Brighton and Sussex Medical School
    University of Sussex
    Brighton, United Kingdom

    Disclosures

    Lesley Fallowfield, DBE, BSc, DPhil, FMedSci, has the following relevant financial relationships: 
    Consultant or advisor for: AstraZeneca; Eisai Inc.; Voluntis (former)
    Speaker or member of speakers bureau for: AbbVie, Inc.; AstraZeneca; Clovis Oncology; Eli Lilly and Company; Exact Sciences Corporation; Merck Sharp & Dohme; Novartis; Pfizer, Inc.; Puma Biotechnology; Roche; Seagen Inc.; Takeda
    Research funding from: Eli Lilly and Company; Nanostring

  • Eric Lim, MBChB, MD, MSc, FRCS(C-Th)

    Consultant Thoracic Surgeon
    Royal Brompton Hospital
    Professor of Thoracic Surgery
    Imperial College London
    London, United Kingdom 

    Disclosures

    Eric Lim, MBChB, MD, MSc, FRCS(C-Th), has the following relevant financial relationships: 
    Consultant or advisor for: AstraZeneca; Bristol Myers Squibb Company; BeiGene (Beijing) Co., Ltd; Covidien/Medtronic; Johnson and Johnson/Ethicon; Medela; Roche
    Speaker or member of speakers bureau for: AstraZeneca; Bristol Myers Squibb Company; Covidien/Medtronic; Johnson and Johnson/Ethicon; Medela; Roche
    Research funding from: Guardant Health, Inc.; Medela; Medtronic, Inc.
    Contracted researcher for: Clearbridge Biomedics; Medela; Screencell
    Patent beneficiary of: Imperial Innovations - P52435GB (microfluidic staining); P57988GB (blood based COLD-PCR primer development)
    Other: Received funds for the development of My Cancer Companion patient education app from: AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; Bayer; Lilly Oncology; Takeda Oncology

Editor

  • Megan Cannon, PhD

    Medical Education Director, WebMD Global, LLC

    Disclosures

    Megan Cannon, PhD, has no relevant financial relationships.

Compliance Reviewer

  • Yaisanet Oyola, MD

    Associate Director, Accreditation and Compliance

    Disclosures

    Yaisanet Oyola, MD, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

Medscape

Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

    College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.

    Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC

Early-Stage Resectable Non-Small Cell Lung Cancer: Sharing Patient Perspectives

Authors: Solange Peters, MD, PhD; ​Anne-Marie Baird, PhD; ​​​Lesley Fallowfield, DBE, BSc, DPhil, FMedSci; ​​​Eric Lim, MBChB, MD, MSc, FRCS(C-Th)Faculty and Disclosures
THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC Released: 5/4/2023

Valid for credit through: 5/4/2024, 11:59 PM EST

processing....

Educational Impact Challenge

The goal of this activity is for learners to be better able to manage early-stage resectable non-small cell lung cancer (NSCLC) by improving their understanding of key aspects of management and communication with patients throughout the disease journey.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print